Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats
The data indicate that the hG551D rats have better outcomes during infection when treated with ivacaftor compared to the vehicle group. Rats have increased weight gain, increased CFTR protein function, and decreased mucus accumulation, despite the persistence of infection and inflammation. These data suggest that ivacaftor improves tolerance of infection, rather than eradication, in this rat model.
Authors
- Ashley M. Oden
- Johnathan D. Keith
- Gretchen E Bollar (ORCID: https://orcid.org/0000-0002-6242-5317)
- Ian H. Doty
- Susan E. Birket (ORCID: https://orcid.org/0000-0002-6353-6596)
- Mikayla Murphree-Terry (ORCID: https://orcid.org/0000-0001-7390-9512)
Institutions
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Respiratory Research
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1186/s12931-024-03029-0
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Cystic Fibrosis Foundation
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases